Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.
Richard E ClarkAmmar A BasabrainGemma M AustinAlison K HolcroftSandra LoaizaJane F ApperleyChristopher LawLaura ScottAlexandra D ParryLaura Jayne BonnettClaire M LucasPublished in: Cancers (2021)
These data confirm that high diagnostic CIP2A levels correlate with subsequent disease progression and treatment failure. CIP2A is a simple diagnostic biomarker that may be useful in planning treatment strategies.